Drug Profile


Alternative Names: rTBP 2; TBP 2; Tumour necrosis factor binding protein 2

Latest Information Update: 01 Mar 2000

Price : $50

At a glance

  • Originator Yeda
  • Developer Merck Serono; Yeda
  • Class Antimalarials
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malaria; Septic shock

Most Recent Events

  • 01 Mar 2000 Discontinued-Preclinical for Malaria in Israel (Unknown route)
  • 01 Mar 2000 Discontinued-Preclinical for Septic shock in Switzerland (Unknown route)
  • 01 Mar 2000 Discontinued-Preclinical for Septic shock in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top